Video Interview: BC Platforms Making Genomic Data Meaningful
This article was originally published in Scrip
BC Platforms CEO Tero Silvola explains to Mike Ward, global director of content for Informa's pharma insights portfolio, how his company is working to solve the challenge pharma and biotech firms face managing and analyzing complex big data in a systematic, standardized and secure manner to improve R&D productivity, clinical decision making and patient outcomes. Founded in 1997, the Switzerland-based biocomputing company has developed technology that can integrate proprietary and public genomic data with wellbeing and healthcare data. The company already has more than 200 clients from academia and industry and is looking to cement its ambition of becoming the market leader in genome knowledge brokering.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.